Kelly Huang, PhDBusiness Wire
Cardiovascular imaging AI firm Elucid has named Kelly Huang, PhD, as the company's president and CEO.
Huang joins Elucid after serving as chief operating officer (COO) for Cardea Bio, a mass producer of biocompatible semiconductors that was acquired by Paragraf in 2023. Prior to that, he held the positions of COO and head of Nutra-Theraputic at L-Nutra. Huang has also been president, CEO, and board director at Obalon Therapeutics, a publicly traded medical device company. He holds a PhD in chemical engineering from Stanford University.
Huang’s appointment as CEO follows Elucid’s $80 million Series C fundraising in the fourth quarter of 2023, led by Elevage Medical Technologies, which aims to help further commercialization and expansion plans. Elucid also moved into new headquarters in June as part of its acceleration toward commercial launch.
Elucid is preparing to commercialize its flagship PlaqueIQ plaque analysis software, an image analysis algorithm that quantifies and characterizes plaque on CT angiography exams.
